Skip to content

Trial Summary

A phase 3 study of MK-4280 plus MK-3475 (pembrolizumab) vs. regorafeneb in 3L+ mCRC

Acronym:

MK4280A-700

ACTRN/NCT /ethics:

Scientific title:

A phase 3 study of MK-4280 plus MK-3475 (pembrolizumab) vs. regorafeneb in 3L+ mCRC

Sponsor / Cooperative group:

Trial & Patient Characteristics

Cancer TypeBowel and colon
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date-
Anticipated End Date-

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6140
Principal InvestigatorProfessor Tim Price
Recruitment StatusNot Yet Recruiting